Clinical Trials Logo
  1. Home
  2. Diabetic Nephropathy
  3. NCT01015937
  4. Details
NCT01015937 Clinical Trial

Effect of Turmeric on Diabetic Nephropathy

Diabetic Nephropathy Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT01015937
Other study ID # 3997
Secondary ID
Status Completed
Phase N/A
First received November 16, 2009
Last updated November 17, 2009
Start date March 2008
Est. completion date August 2009

Study information
Verified date November 2009
Source Shaheed Faghihi Hospital
Contact n/a
Is FDA regulated No
Health authority Iran: Ministry of Health
Study type Interventional

Clinical Trial Summary

The purpose of this study is to investigate whether turmeric is effective in improvement of diabetic nephropathy and in decrease in the amount of proteinuria and cytokine levels.

Description:

Diabetic nephropathy is leading cause of ESRF that many therapy recommended for it. In this study, we investigate effect of turmeric on diabetic nephropathy, thus we selected diabetic nephropathy patients and divided them into 2 groups. One group received turmeric + ACE inhibitor + Angiotensin II receptor blocker (ARB) and the second group received only ACE inhibitor + ARB.

Recruitment information / eligibility
Status Completed
Enrollment 50
Est. completion date August 2009
Est. primary completion date June 2009
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

- diabetic nephropathy

- more than 300 mg proteinuria/day

- age more than 18 years old

Exclusion Criteria:

- DM type 1

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

Intervention

Drug:
• Turmeric extract
turmeric 500 mg TID for 45 days
• Angiotensin-converting enzyme (ACE) inhibitor + Angiotensin-II type 1 receptor (ATI) blocker
maximum dosage as patient tolerated for 45 days

Locations
Country Name City State
Iran, Islamic Republic of Clinic Shiraz Fars

Sponsors (2)
Lead Sponsor Collaborator
Shaheed Faghihi Hospital Shiraz University of Medical Sciences

Country where clinical trial is conducted

Iran, Islamic Republic of, 

See also
  Status Clinical Trial Phase
Recruiting NCT04562025 - Clinical Research of UC-MSCs in the Treatment of Diabetic Nephropathy N/A
Not yet recruiting NCT03658317 - Renal Resisitive Index as an Indicator of the Progression of Diabetic Nephropathy N/A
Recruiting NCT02501772 - The Evaluation of Effect of Sanyinjiao (SP6) Acupressure on Early Diabetic Nephropathy N/A
Completed NCT02276196 - Effect of LIXIsenatide on the Renal System Phase 4
Completed NCT02829177 - Microalbuminuria and Allopurinol in Type 1 Diabetes Phase 4
Completed NCT02251067 - Phase 2 Study to Evaluate Safety & Efficacy of VPI-2690B in Diabetic Nephropathy Patients Phase 2
Completed NCT01440257 - A Study to Evaluate the Effect of CCX140-B on Urinary Albumin Excretion in Subjects With Type 2 Diabetes and Albuminuria Phase 2
Active, not recruiting NCT01273675 - An Investigation on the Effect of Candesartan on Early Diabetic Nephropathy N/A
Terminated NCT01129557 - Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney Disease Phase 4
Completed NCT00317954 - Spironolactone in Diabetic Nephropathy Phase 4
Active, not recruiting NCT02237352 - Mechanisms of Diabetic Nephropathy in Ecuador
Not yet recruiting NCT05061459 - The Expression of circANKRD36 as a New Biomarker of Diabetic Nephropathy
Completed NCT01935167 - To Determine the Efficacy and Safety of DW1029M on Microalbuminuria in Patients With Diabetic Nephropathy Phase 2
Recruiting NCT01673204 - Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy Phase 4
Completed NCT01726816 - Efficacy and Safety Study of Probucol in Patients With Diabetic Nephropathy Phase 2
Recruiting NCT01458158 - Matrix Metalloproteinases in Atherosclerosis of Chronic Kidney Disease N/A
Completed NCT01476501 - Vitamin D Supplementation in Diabetic Nephropathy Phase 2
Completed NCT01447147 - A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Diabetic Nephropathy Phase 2
Completed NCT01003236 - Evaluating the Renoprotective Effect of Milk Thistle Extract on Patients With Type II Diabetic Nephropathy Phase 2
Completed NCT00535925 - Nephropathy In Type 2 Diabetes and Cardio-renal Events Phase 4

External Links